On October 28, 2024, the company reported that its revenue growth for 3Q 24 was roughly half that reported in 2Q 24. Still, TransMedics assured investors that the disappointing growth was not caused by a change in competitive dynamics or market share loss. Despite this assurance, the news caused the price of TransMedics stock to drop almost 30%, from $126.24 per share on October 28, 2024 to $88.50 per share on October 29, 2024.